Clinical Trial

Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease

Study acronym: INTERCEPT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this study is to understand the safety, tolerability, and potential efficacy of an injected immune therapy called RP2 to treat oral precancer conditions and prevent progression to an oral cancer. The name of the study drug involved in this study is: -RP2 (a genetically modified live Herpes Simplex V-1 strain)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-30; most recent amendment 2026-04-20.
Status change: Not Yet Recruiting → Recruiting 2025-04-14
Trial Details
NCT Number NCT06623110
Lead Sponsor Glenn J. Hanna
Collaborators: Replimune, Inc.
Conditions High-Risk Oral Precancerous Disease
Enrollment 25 participants
Start Date 2025-01-01
Primary Completion 2027-01-01 (estimated)
Study Completion 2029-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-23